EDGAR Filing Documents for 0001564590-22-029913

Form 8-K - Current report:

SEC Accession No. 0001564590-22-029913

Filing Date

2022-08-23

Accepted

2022-08-23 08:30:37

Documents

Period of Report

2022-08-19

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	acer-8k_20220819.htm iXBRL	8-K	56298
2	EX-10.2	acer-ex102_6.htm	EX-10.2	54971
3	EX-10.3	acer-ex103_7.htm	EX-10.3	98251
	Complete submission text file	0001564590-22-029913.txt		375272

Data Files

Seq	Description	Document	Type	Size
4	XBRL TAXONOMY EXTENSION SCHEMA	acer-20220819.xsd	EX-101.SCH	5581
5	XBRL TAXONOMY EXTENSION LABEL LINKBASE	acer-20220819_lab.xml	EX-101.LAB	20086
6	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	acer-20220819_pre.xml	EX-101.PRE	11931
8	EXTRACTED XBRL INSTANCE DOCUMENT	acer-8k_20220819_htm.xml	XML	3694

Mailing Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458

Business Address ONE GATEWAY CENTER (300 WASHINGTON ST.) SUITE 356 NEWTON MA 02458 (844) 902-6100

Acer Therapeutics Inc. (Filer) CIK: 0001069308 (see all company filings)